Literature DB >> 6643789

Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A.

J L Marx, R Auerbach, P Possick, R Myrow, A H Gladstein, A W Kopf.   

Abstract

Two patients are reported who were treated with 8-methoxypsoralen and ultraviolet A (PUVA) for psoriasis and developed cutaneous lesions of malignant melanoma in situ (atypical melanocytic hyperplasia). One patient received 324.5 joules/cm2 of UVA. Seven months after discontinuing therapy, he developed a superficial spreading melanoma in situ in association with an intradermal nevus on the left posterior thoracic area. The second patient received 2,802 joules/cm of UVA. While on PUVA therapy she developed an in situ lentigo melanoma on her lower lip. To our knowledge only one other psoriatic patient and one patient with vitiligo have developed malignant melanomas after PUVA therapy, so that an increased incidence of malignant melanomas after PUVA therapy, so that an increased incidence of malignant melanoma following PUVA is not documented.

Entities:  

Mesh:

Year:  1983        PMID: 6643789     DOI: 10.1016/s0190-9622(83)70207-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  Photochemotherapy. A reappraisal of its use in dermatology.

Authors:  H Moseley; J Ferguson
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma.

Authors:  A J Swerdlow; J S English; R M MacKie; C J O'Doherty; J A Hunter; J Clark; D J Hole
Journal:  BMJ       Date:  1988-09-10

3.  Nodular malignant melanoma and multiple squamous cell carcinomas in a patient treated by photochemotherapy for psoriasis.

Authors:  D Kemmett; H Reshad; H Baker
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-01

4.  PUVA therapy for psoriasis.

Authors:  H Baker
Journal:  J R Soc Med       Date:  1984-07       Impact factor: 5.344

Review 5.  Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?

Authors:  B Lindelöf
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

6.  Isolation of a Melanoblast Stimulator from Dimocarpus longan, Its Structural Modification, and Structure-Activity Relationships for Vitiligo.

Authors:  Jae-Won Song; Sunju Choi; Gayeong Kim; Hyang Bok Lee; P Sankara Rao; Jeonghyun Shin; Eun Ki Kim; Dong-Gyu Cho
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

7.  Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population.

Authors:  Shany Sherman; Noa Kremer; Adam Dalal; Efrat Solomon-Cohen; Einav Berkovich; Yehonatan Noyman; Maya Ben-Lassan; Assi Levi; Lev Pavlovsky; Hadas Prag Naveh; Emmilia Hodak; Iris Amitay-Laish
Journal:  Acta Derm Venereol       Date:  2020-12-09       Impact factor: 3.875

8.  Dermoscopic findings of psoralen and ultraviolet A therapy lentigines resembling melanoma in a patient with mycosis fungoides.

Authors:  Mai Sakurai; Motoki Nakamura; Kyoko Ikumi; Hiroshi Kato; Akimichi Morita
Journal:  J Dermatol       Date:  2021-08-04       Impact factor: 3.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.